Sigma Planning Corp acquired a new stake in Shire PLC (NASDAQ:SHPG) during the second quarter, according to its most recent 13F filing with the SEC. The fund acquired 1,399 shares of the biopharmaceutical company’s stock, valued at approximately $258,000.

A number of other institutional investors have also recently bought and sold shares of SHPG. Meeder Asset Management Inc. purchased a new position in Shire PLC during the second quarter valued at $289,000. Security National Trust Co. purchased a new position in Shire PLC during the second quarter valued at $641,000. John G Ullman & Associates Inc. purchased a new position in Shire PLC during the second quarter valued at $1,495,000. Goelzer Investment Management Inc. purchased a new position in Shire PLC during the second quarter valued at $3,136,000. Finally, Kwmg LLC purchased a new position in Shire PLC during the second quarter valued at $244,000. Hedge funds and other institutional investors own 24.61% of the company’s stock.

Shire PLC (NASDAQ:SHPG) traded up 2.09% during mid-day trading on Friday, reaching $200.60. 2,264,693 shares of the company were exchanged. The stock has a market capitalization of $59.75 billion, a price-to-earnings ratio of 41.69 and a beta of 1.11. Shire PLC has a 12-month low of $147.60 and a 12-month high of $231.32. The company’s 50 day moving average price is $195.09 and its 200-day moving average price is $182.40.

Shire PLC (NASDAQ:SHPG) last released its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.35. The business earned $2.43 million during the quarter, compared to the consensus estimate of $2.28 billion. Shire PLC had a net margin of 13.19% and a return on equity of 17.70%. The firm’s revenue for the quarter was up 55.9% compared to the same quarter last year. During the same quarter last year, the firm earned $2.63 earnings per share. On average, equities research analysts forecast that Shire PLC will post $12.93 earnings per share for the current fiscal year.

The firm also recently announced a dividend, which will be paid on Friday, October 7th. Investors of record on Friday, September 9th will be given a $0.139 dividend. The ex-dividend date is Wednesday, September 7th. Shire PLC’s dividend payout ratio (DPR) is currently 15.63%.

Several research firms have weighed in on SHPG. Jefferies Group reiterated a “buy” rating and set a $262.00 price objective on shares of Shire PLC in a research report on Wednesday, September 7th. Shore Capital reiterated a “buy” rating on shares of Shire PLC in a research report on Tuesday, August 30th. TheStreet cut shares of Shire PLC to a “hold” rating in a research report on Thursday, August 4th. Zacks Investment Research upgraded shares of Shire PLC from a “sell” rating to a “hold” rating in a research report on Thursday, August 4th. Finally, RBC Capital Markets reiterated an “outperform” rating on shares of Shire PLC in a research report on Wednesday, August 3rd. Four analysts have rated the stock with a hold rating and twenty-four have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $230.67.

About Shire PLC

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

5 Day Chart for NASDAQ:SHPG

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.